Hot Deals:
adtech 73.00 (1.39 %) agarwal bolts 1,200.00 (0.00 %) amol minechem 601.00 (0.17 %) anand i-power 20.00 anglo french drugs 745.00 (-0.67 %) apl metals 40.00 (-2.44 %) arkfin investments 50.00 arohan 150.00 (3.45 %) assam carbon 215.00 (2.38 %) atlas copco 10,000.00 (1.01 %) auckland international 129.00 (-0.77 %) av thomas 16,800.00 (0.00 %) axles 500.00 (2.04 %) balmer lawrie 202.00 (1.00 %) bharat hotels 300.00 (3.45 %) bima mandi 235.00 (-2.08 %) bira 600.00 (0.84 %) boat 1,350.00 (1.50 %) c & s electric 600.00 (1.69 %) cable corporation 13.00 (-0.76 %) capgemini 11,500.00 (0.88 %) care health 179.00 (-0.56 %) carrier aircon 535.00 (1.90 %) cial 285.00 (1.79 %) csk 183.00 (-0.54 %) dalmia refract 195.00 (2.63 %) dfm foods 467.00 dsp merrill lynch 1,000.00 east india pharma 39.00 (-2.50 %) eaton fluid 425.00 (2.66 %) electronica plastic 2,100.00 (-0.99 %) elgi ultra 400.00 elofic 2,050.00 (-0.97 %) esl steel 45.00 (2.27 %) fincare business 72.00 (2.86 %) fincare sfbl 202.00 (1.00 %) finopaytech 156.00 (0.65 %) flipkart india 231,001.00 (0.00 %) frick india 15,800.00 (3.95 %) gkn driveline 1,350.00 (3.05 %) go digit general insurance ltd 354.00 (1.14 %) godavari bio 71.00 (1.43 %) goodluck defence 240.00 (-1.23 %) group pharma 300.00 gynofem healthcare 81.00 (1.25 %) hdb financial 1,050.00 (5.53 %) hdfc ergo 370.00 (1.70 %) hdfc securities 11,000.00 (1.85 %) hella india 810.00 (1.25 %) hero fincorp 1,685.00 (-0.12 %) hexaware 885.00 (0.57 %) hicks 1,450.00 (2.11 %) hira ferro 155.00 (3.33 %) honeywell electrical 4,500.00 (2.27 %) ikf finance 243.00 (1.25 %) incred financial 109.00 (3.81 %) incred holdings 151.00 (0.67 %) india carbon 1,175.00 (0.43 %) india exposition 140.00 (3.70 %) indian potash 2,900.00 (-1.69 %) indo alusys 25.75 (-0.96 %) indofil 790.00 (-1.25 %) infinite computer 405.00 (1.25 %) inkel 21.50 (2.38 %) ixigo 143.00 (-1.38 %) jana small finance bank 75.00 kel 625.00 (1.63 %) kial 122.00 (-2.40 %) klm axiva 15.00 (-1.32 %) kurlon limited 1,250.00 (2.46 %) lava 70.00 (-1.41 %) mahindra rural mrhfl 100.00 manipal housing 74.00 (2.07 %) manjushree technopack 1,333.00 (-1.26 %) martin & harris 1,020.00 (0.99 %) merino 3,250.00 (1.56 %) minosha 282.00 (0.71 %) mitsubishi heavy 207.00 (-0.48 %) mkcl 421.00 (-0.94 %) mobikwik 570.00 (-0.87 %) mohan meakin 1,950.00 (2.63 %) mohfl 12.80 (-1.54 %) msei 1.14 (-0.87 %) msil 35.00 (-2.78 %) nayara energy 480.00 (1.05 %) nayara energy ncd 285.00 (1.79 %) ncdex 275.00 ncl buildtek 260.00 (1.56 %) ncl holdings 85.00 (3.66 %) nsdl 777.00 (3.60 %) nse 4,500.00 (-0.99 %) orbis financial 280.00 (1.82 %) oswal minerals 60.10 (-1.48 %) otis 3,770.00 (0.53 %) oyo 55.00 (-1.79 %) panasonic appliances 211.00 (0.48 %) paymate india 514.00 (-0.19 %) pharmeasy 10.00 (1.01 %) pharmed limited 480.00 (2.13 %) philips domestic 600.00 (1.69 %) philips india 920.00 (-0.54 %) pnb metlife 70.00 proyuga adtech 25.00 purity flexpack 20.00 ramaraju surgical 275.00 (-1.79 %) rapido 16,650.00 (0.03 %) rasoi 31,500.00 (0.32 %) reliance gic 480.00 (1.05 %) resins plastics 415.00 (-1.89 %) ring plus aqua 530.00 (0.95 %) rrl 1,275.00 (2.00 %) rrp s4e innovation 282.00 (0.71 %) sab miller 375.00 (-1.32 %) sbi amc 1,670.00 (1.21 %) sbi general insurance 600.00 (3.45 %) scottish assam 440.00 (-1.35 %) shriram life 261.00 (0.38 %) sigachi laboratories 36.00 (-2.70 %) signify 1,400.00 (3.70 %) smile microfinance 54.00 (3.85 %) sportskeeda 3,303.00 sterlite power 522.00 (-0.57 %) studds 975.00 (0.52 %) svsml 315.00 (2.94 %) swiggy 345.00 (-1.43 %) t stanes 770.00 (1.99 %) tata capital 920.00 (2.22 %) teesta agro 77.00 (-6.21 %) trl krosaki 1,290.00 (-0.77 %) urban tots 52.00 (4.00 %) utkarsh coreinvest 285.00 (-1.72 %) vadilal dairy 10.00 vikram solar 230.00 (-4.17 %) waree energies 1,880.00 (1.62 %)
×

Arch Pharmalabs Share Price

Arch PharmaLabs Limited Fundamentals

Company Name
Arch PharmaLabs Limited
Scrip Name
Arch Pharmalabs
Last Traded Price
90.10
+ 0.11 %
Sector
Other
PAN No.
AACCM0306Q
Face Value
10
No. of Outstanding Shares
151,923,000
EPS
3.864
PE ratio
23.318
Market Capitalization
1,368.83 Crore
Book value
39.936
P/BV
2.2561
ISIN No.
INE182F01017
Available on
nsdlcdsl
ROFR Require
No
Day High
90.10
Day Low
90.10
52 Week High
90.10
52 Week Low
87.00
Lifetime High
90.10
Lifetime Low
50.00

Arch Pharmalabs Price Performance

Arch Pharma Labs Limited Delisted Share - Company Overview

ARCH PHARMA LABS LIMITED is a pharmaceutical company aligned across two business verticals viz. Products and Services. The Products business of the company comprises the manufacture and sale of Active Pharmaceutical Ingredients (“API”) and Intermediates to innovator and generic pharmaceutical players in both domestic and international markets including the regulated markets. In services business of the company includes Contract Research and Manufacturing Services (“CRAMS”). Currently, the company owns and manages 9 multipurpose manufacturing facilities.

The Company has a diversified portfolio and offers more than 120 products ( over 65 APIs and over 55 Intermediates) across various therapeutic segments, such as lipid-lowering agents, oncology, anti-platelet agents, anti-asthmatic,anti-retroviral, anti-anginal, calcium channel blockers, anti-hypertensive,anti-histamine, anti-diabetic, anti-protozoal, anti-fungal, anti-emetic, proton pump inhibitors, expectorant, anti-depressant, decongestant, anti-convulsant, psychostimulant, hypnotic, anti-parkinsonian, anti-gout, analgesic, and others.

The Company provides contract manufacturing, custom synthesis, and contract research services comprising route selection, process development, optimization, analytical development, stability studies, safety studies, scale-up to technology transfer, clinical-trial manufacturing, and commercial manufacture.

Arch Pharmalabs Limited has technology tie-ups with Codexis (USA), Orochem Technologies (USA), and DSM (Netherlands). The use of these technologies helps the company to implement various green chemistry initiatives which are not only environmentally friendly but also reduce production costs.

Incorporation Details of Arch Pharma Labs Limited

CIN of Arch Pharma Labs

U24231MH1993PLC150891

Registration Date of Arch Pharma Labs

02 April 1993

Category/Sub-category of Arch Pharma Labs

Company Limited by Shares

Arch Pharma Labs Registered office address and contact details

3rd Floor, Titanic Building, Chandivali Farm Road,

Nr. HDFC Bank, Andheri (East), Mumbai - 400072.

Tel. : +91-22-4287 1210

Arch Pharma Labs Registrar and Transfer Agent address and contact details

Link Intime India Private Limited

C-101, 247 Park, L.B.S Marg,

Vikhroli (West), Mumbai - 400083,

Tel: 022-25946970

Principal Business Activities of Arch Pharma Labs Limited

Name and Description of main products/services

NIC Code of the product/service

% to total turnover of the Company

Pharmaceutical products

21002 & 21005

100%

Board of Directors of Arch Pharma Labs Limited

Mr. Ajit Kamath (Chairman & Managing Director)

Mr. Rajendra Kaimal (Executive Director & CFO)

Mr. Ashish Ujagare (Executive Director)

Dr. Sunil Pitroda (Independent Director)

Particulars of Subsidiaries and Associates Companies of Arch Pharma Labs 

Name of the Company

Subsidiary/Associate

% of shares held

Arch Life SciencesLimited

Subsidiary

58.46%

Arch FinechemicalsLimited

Subsidiary

88.95%

Arch Pharmalabs FZLLC

Subsidiary

100.00%

Kobo Biotech Limited

Associate

44.95%

Shareholding Pattern of Arch Pharma Labs Limited (As of 31-03-2020)

S. No.

Shareholders’ Name

Number of shares

% of total Shares of the company

1

Arch Impex Private Limited

5,54,05,664

36.47%

2

Arch PharmachemLimited

2,11,81,000

13.94%

3

ArchAgroIndustriesPrivate Limited

61,54,754

4.05%

4

AMR InvestmentsPrivate Limited

19,76,681

1.30%

5

Arch Herbals Private limited

62,42,076

4.11%

6

Public Shareholding

6,09,62,901

40.12%

 

Total

15,19,23,076

100.00%

Industry Outlook

The Global pharmaceutical industry is valued at around US$ 1250 billion. The US market alone accounts for 48% of the market. India and China each stand at US$ 53 billion and US$ 190 billion respectively. India is the largest provider of generic drugs and is fulfilling around 20% of the global demand.

In the Active Pharmaceutical Ingredients (API) Industry, if we see the units approved by USFDA, US leads with 28% approval rating, Europe with 26%, and India & China with 18% and 13% respectively. It is the best time for India to focus on building and improving its API manufacturing and export capabilities. According to Statistics, the Indian API market is projected to grow at a CAGR of 8.57% from 2020 to 2026. The Government of India has announced Rs. 6,940 Crore Production Linked Incentive (PLI) scheme to boost drug manufacturing in India. The scheme is mainly aimed at reducing imports through the promotion of domestic manufacturing of Active Pharmaceutical Ingredients (APIs) and Drug Intermediates.

Pharmaceutical Companies are continuously increasing outsourcing research activities to academic and private contract research organizations (CROs) to become and stay competitive in the market. After the COVID 19 pandemic, the pharmaceutical industry has gotten a new direction and is currently experiencing dynamic changes. That is why to reduce their R&D expenses, the companies to a significant extent are now relying on outsourcing service providers. Based on this, the opportunities available to India are Custom Chemical Synthesis or CCS, clinical trials, and contract manufacturing or CRAMS. However, the most scalable opportunity for Indian companies lies in contract manufacturing or CRAMS. This is because CRAMS supplies are linked to the success of a product post commercialization and can provide relatively stable revenues.

 

Annual Report

Arch PharmaLabs Annual Report 2021-22

Download

Arch PharmaLabs Annual Report 2020-21

Download
Wealth Wisdom - WWIPL
Support Megha Support Neha